NasdaqGS:TARSPharmaceuticals
How China TP-03 Approval and US$15 Million Milestone Could Shape Tarsus Pharmaceuticals (TARS) Investors
In March 2026, Tarsus Pharmaceuticals announced that its partner Grand Pharmaceutical Group secured National Medical Products Administration approval in China for TP-03 (XDEMVY) to treat Demodex blepharitis, triggering a US$15,000,000 milestone payment to Tarsus and confirming TP-03 as the first approved therapy addressing the disease’s root cause in Greater China.
This approval not only validates TP-03’s clinical and regulatory profile outside the U.S., but also opens a new revenue stream...